Cholecystokinin B Receptor from Human Jurkat Lymphoblastic T Cells Is Involved in Activator Protein-1-Responsive Gene Activation

SUMMARY The aim of this study was to analyze the role of cholecystokinin (CCK B ) receptor in human lymphoblastic Jurkat T cells. We investigated the trophic effect resulting from activation of such a receptor by using the reporter gene strategy. For this purpose, we transiently transfected Jurkat T cells with the reporter plasmid p[(TRE)3-tk-Luc] and found that CCK-8 was able to dose-dependently induce luciferase expression related to activator protein-1 (AP-1) activation with a maximal response identical to that obtained with compounds known to activate AP-1 complex (quantitatively, the same level of induction was obtained with 1 nM 12-O-tetradecanoylphorbol-13-acetate, 100 M diacylglycerol, or 4 nM epidermal growth factor). The involvement of the CCK B receptor in such a stimulation was demonstrated by the inhibiting effect of the selective CCK B receptor antagonist 158. This effect was confirmed in COS-7 cells transfected with the cDNA of CCK B receptor cloned from Jurkat T cells. To better understand the AP-1-dependent luciferase expression in Jurkat T cells, we tested two specific inhibitors of serine/threonine phosphatases-1 and -2A: okadaic acid and calyculin A. These compounds strongly increased the phorbol-12-myristate-13-acetate response, whereas we have not observed a contribution of phosphatase inhibitors on a CCK-8-induced luciferase activity. To confirm that CCK B receptors are involved in AP-1 response, we investigated the CCK-8 effect on interleukin-2 expression, a natural endogenous gene regulated by several factors, including AP-1. In Jurkat T cells activated by phorbol-12-myristate-13-acetate and phytohemagglutinin, CCK-8 induced IL-2 expression. This induction was abolished by PD-135,158. Our results indicate that CCK-8 exerts a trophic effect in Jurkat T cells through stimulation of CCK B receptors by modulation of expression of AP-1-regulated genes. Several studies have shown that various gastrointestinal peptides may be involved in the control of proliferation of various tissues and neoplastic cells (1). For example, CCK was shown to increase growth of tumors in nude mice bearing transplanted pancreatic cancer tissues (2). CCK is also known to increase the number of animals developing nitrosamine-induced pancreatic cancers (3), and CCK was shown to increase the rate of growth of cultured pancreatic cancer cells (2). Similar observations were described for bombesin/ gastrin-releasing peptide in human glioblastoma in vitro and in vivo in small-cell lung carcinoma, prostatic, mammary, and pancreatic cancer cell lines (1). In addition, gastrointestinal peptides can function as autocrine growth factors in neoplastic tissues as shown for bombesin/gastrin-releasing peptide in small-cell lung carcinoma cells, for gastrin an

Cholecystokinin B Receptor from Human Jurkat Lymphoblastic T Cells Is Involved in Activator Protein-1-Responsive Gene Activation

International audienc